Home Cart Sign in  
HazMat Fee +

There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.

Type HazMat fee for 500 gram (Estimated)
Excepted Quantity USD 0.00
Limited Quantity USD 15-60
Inaccessible (Haz class 6.1), Domestic USD 80+
Inaccessible (Haz class 6.1), International USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic USD 100+
Accessible (Haz class 3, 4, 5 or 8), International USD 200+
Chemical Structure| 430-99-9 Chemical Structure| 430-99-9

Structure of 430-99-9

Chemical Structure| 430-99-9

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Product Citations

Anthony G. Dodge ; Calvin J. Thoma ; Madeline R. O’Connor ; Lawrence P. Wackett ;

Abstract: Microbial response to toxic fluoride anion has traditionally been studied by adding inorganic fluoride salts to growth media. Fluoride is known to spontaneously transit the membrane as hydrogen fluoride (HF) and manifests significant toxicity in the cytoplasm. The present study investigated how microbes respond to high levels of HF generated directly in the cytoplasm to better understand potential limits of microbial defluorination of organofluorine compounds. For that purpose, Pseudomonas putida ATCC 12633 was engineered to express a defluorinase enzyme from Delftia acidovorans strain B that had high activity in producing growth-supporting from organofluorinated compounds of xenobiotic origin. Genome annotation predicted the growth of P. putida ATCC 12633 on all possible chiral products from 2-fluoropropionic acid and α-fluorophenylacetic acid when defluroinases are expressed. The defluorinase was shown to have complete enantioselectivity for (S)-fluoro substrates via experimental and computational modeling methods. The bacterium grew to a high turbidity with stoichiometric release of fluoride from the (S)-enantiomers into the medium. The highest yield of fluoride obtained was 50 mM with 2-fluoropropionic acid as the growth substrate. The growth yield was significantly lowered by 41% with α-fluorophenylacetic acid or 2-fluoropropionic acid compared to or , respectively. Fluoride stress was also indicated by longer lag phases, slower growth, and cell morphology changes on fluorinated substrates or the cognate with NaF in the medium. In total, these studies show the potential for engineering bacterial defluorination of non-natural substrates within limits posed by fluoride stress. IMPORTANCE: Society uses thousands of organofluorine compounds, sometimes denoted per- and polyfluoroalkyl substances (PFAS), in hundreds of products, but recent studies have shown some to manifest human and environmental health effects. As a class, they are recalcitrant to biodegradation, partly due to the paucity of fluorinated natural products to which microbes have been exposed. Another limit to PFAS biodegradation is the intracellular toxicity of fluoride anion generated from C-F bond cleavage. The present study identified a broader substrate specificity in an enzyme originally studied for its activity on the natural product fluoroacetate. A recombinant Pseudomonas expressing this enzyme was used here as a model system to better understand the limits and effects of a high level of intracellular fluoride generation. A fluoride stress response has evolved in bacteria and has been described in Pseudomonas spp. The present study is highly relevant to organofluorine compound degradation or engineered biosynthesis in which fluoride anion is a substrate.

Purchased from AmBeed:

Alternative Products

Product Details of [ 430-99-9 ]

CAS No. :430-99-9
Formula : C3H3FO2
M.W : 90.05
SMILES Code : C=C(F)C(O)=O
MDL No. :MFCD03424474
InChI Key :TYCFGHUTYSLISP-UHFFFAOYSA-N
Pubchem ID :2782523

Safety of [ 430-99-9 ]

GHS Pictogram:
Signal Word:Danger
Hazard Statements:H302-H314
Precautionary Statements:P260-P264-P270-P280-P301+P330+P331-P303+P361+P353-P304+P340-P305+P351+P338-P310-P363-P405-P501
Class:8
UN#:3261
Packing Group:

Computational Chemistry of [ 430-99-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 6
Num. arom. heavy atoms 0
Fraction Csp3 0.0
Num. rotatable bonds 1
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 17.88
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

37.3 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

0.85
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

0.69
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

0.97
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

0.16
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.1
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

0.55

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-0.77
Solubility 15.4 mg/ml ; 0.171 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.05
Solubility 8.02 mg/ml ; 0.089 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.12
Solubility 118.0 mg/ml ; 1.31 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.36 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

2.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.56

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

1.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.12

Application In Synthesis of [ 430-99-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 430-99-9 ]

[ 430-99-9 ] Synthesis Path-Downstream   1~35

  • 1
  • [ 425-83-2 ]
  • [ 430-99-9 ]
  • 2
  • [ 50-00-0 ]
  • [ 598-73-2 ]
  • [ 430-99-9 ]
  • 5
  • [ 433-63-6 ]
  • [ 430-99-9 ]
  • 9
  • [ 57965-29-4 ]
  • [ 430-99-9 ]
  • 10
  • [ 430-99-9 ]
  • [ 425-83-2 ]
  • 13
  • [ 430-99-9 ]
  • [ 52853-55-1 ]
  • N-benzyl-N-(2-methallyl)-α-fluoroacrylamide [ No CAS ]
  • 14
  • [ 430-99-9 ]
  • [ 54436-58-7 ]
  • N-benzyl-N-(pent-4-enyl)-α-fluoroacrylamide [ No CAS ]
  • 15
  • [ 430-99-9 ]
  • [ 145126-90-5 ]
  • N-benzyl-N-(hex-5-enyl)-α-fluoroacrylamide [ No CAS ]
  • 16
  • [ 430-99-9 ]
  • [ 664342-19-2 ]
  • N-(but-3-enyl)-N-(4-fluorobenzyl)-α-fluoroacrylamide [ No CAS ]
  • 17
  • [ 430-99-9 ]
  • [ 664342-18-1 ]
  • N-(but-3-enyl)-N-(4-methoxybenzyl)-α-fluoroacrylamide [ No CAS ]
  • 18
  • [ 430-99-9 ]
  • [ 16522-55-7 ]
YieldReaction ConditionsOperation in experiment
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 0 - 20℃; for 3h;Inert atmosphere; General procedure: Oxalyl dichloride (1.56 mmol, 0.14 mL) was added to the solution of the tested acid (1.72 mmol) in CH2Cl2 (5 mL) and DMF (a drop, about 0.05 mL) at 0 C under Ar atmosphere within 10 min. After the solution was stirred for 3 h at the room temperature, a solution of 3a-i (1.32 mmol) in dichloromethane (8.0 mL) was added at 0 C. The reaction solution was then warmed to room temperature and stirred for overnight. After quenched with saturated NaHCO3 aqueous solution, the mixture was extracted with EtOAc (2×15 mL), and the combined organic layers were washed with brine (20 mL) and dried over NaSO4. After filtration and concentration, the residue was purified by column chromatography to give the acylated product with two rotamers, and the isolated yields were shown in Table 2.
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 20℃; for 2.5h;Cooling with ice; <strong>[430-99-9]2-fluoroacrylic acid</strong> (2.Oeq.) (54 mg) was dissolved in DCM (10 ml)3 drops of DMF were added,Under ice-cooling conditions,Oxalyl chloride (1.7 eq.) (44 [mu] v)In the ice bath conditions for 30min,Remove the ice bath,Natural recovery to room temperature,The reaction was carried out for 2 hours,(4-fluorophenylamino) -6-amino-7- (tetrahydrofuran-3-oxy) quinazoline(1 eq.) (112 mg) was dissolved in DCM (20 ml)Stir at 0 C for 5 min,Was added to the above acid chloride solution,Et3N (4 Oeq.) (169yL) was added,In the ice bath conditions for 30min,Remove the ice bath,After natural recovery to room temperature,The reaction was stirred overnight.After completion of the reaction,Concentrated to dry under reduced pressure crude,Purification by column chromatography (mobile phase 10: lDCM / MeOH) afforded N- (4- (3-chloro-4-fluorophenylamino) -7- (tetrahydrofuran-3-oxy) quinazoline- Yl) -2-fluorobut-2-enamide 80mg
With trichlorophosphate; at 80℃; General procedure: We used indole 7 as starting material to synthesize interediates15a-c by the method reported in the literature [32]. Different substituted acrylic acids were chlorinated by POCl3 to obtain the corresponding acyl chloride at 80 C. Under an ice bath, differently substituted acryl chloride was dissolved in dichloromethane and stirred at 0 C for 10-30 min. Another intermediates 15a-c were added to the above acryl chloride solution, and then added NaHCO3 solid powder, stirred at 0 C for 0.5-3 h. After the reaction was completed, the reaction mixture was filtered and solvent was distilled off under reduced pressure. The crude product was purified using flash chromatography with dichloromethane/methanol(v/v, from 50:1 to 20:1) as eluents
With oxalyl dichloride; N,N-dimethyl-formamide; In dichloromethane; at 20℃; for 2h;Inert atmosphere; Add in a 50mL eggplant bottle<strong>[430-99-9]2-fluoroacrylic acid</strong> 113.07 mg (1.26 mmol).10 mL of dry dichloromethane was added to suspend it.Add oxalyl chloride 115 muL (1.36 mmol) and a drop of DMF,After argon gas was fully replaced, it was allowed to react at room temperature for 2 h.2-Fluoroacryloyl chloride was prepared, and after completion of the reaction, it was charged into a constant pressure dropping funnel.In another 50 mL eggplant bottle, compound 41 300 mg (1.05 mmol) was added.Dissolved in 10 mL of dry dichloromethane,Add 913 muL (5.23 mmol) of DIPEA,After the replacement with argon gas, the acid chloride solution was slowly added dropwise under ice bath.After the completion of the dropwise addition, the reaction was carried out for 1 h. After the reaction was completed by TLC, the reaction mixture was washed with water and brine, dried over anhydrous sodium sulfate andDichloromethane: methanol = 100:1).The product (42) was obtained in 247.00 mg.It was a white solid, yield: 65.80%.

  • 19
  • [ 332061-81-1 ]
  • [ 430-99-9 ]
YieldReaction ConditionsOperation in experiment
With hydrogenchloride; In sodium hydroxide; EXAMPLE 4 Synthesis of 2-fluoroacrylic Acid 31 g of 2-chloro-2-fluoropropionic acid were dissolved in 320 ml of a 2N NaOH solution and heated at 100° C. for 24 h. The medium was subsequently acidified with 140 ml of 2N HCl. The 2-fluoroacrylic acid was extracted with two times 200 ml of diethyl ether. 20 g of 2-fluoroacrylic acid were recovered after evaporation of the ether. The yield of 2-fluoroacrylic acid, based on the amount of 2-chloro-2-fluoropropionic acid employed, was 90percent.
  • 21
  • [ 430-99-9 ]
  • [ 20698-91-3 ]
  • [ 1095714-01-4 ]
YieldReaction ConditionsOperation in experiment
55% Example 149; Compound of Formula (Iaa) wherein M=tert-butoxy, Q=4-tert-butyl-3-methoxybenzoyl, Z=1,3-thiazol-2-yl, X=fluoro, Y=hydroxymethyl, J=1H-pyrazol-1-ylmethylStep 149a. A solution of <strong>[430-99-9]2-fluoroacrylic acid</strong> (2 g, 22 mmol) in dichloromethane (80 mL) was added DCC (4.58 g, 22 mmol). at 0° C. The resulting mixture was stirred at 0° C. for 15 min before addition of a solution of methyl (R)-(-)-mandelate (4.06 g, 24 mmol) and DMAP (136 mg, 0.11 mmol) in 20 mL of dichloromethane. The mixture was stirred at rt for 16 h before being filtered and the organic solution was washed with brine, dried (Na2SO4) and evaporated. The residue was chromatographed (silica, hexane-EtOAc) to give the desired compound (2.9 g, 55percent) as white crystals.1H NMR (CDCl3) 7.50 (m, 2H), 7.43 (m, 3H), 6.09 (s, 1H), 5.83 (dd, 1H), 5.45 (dd, 1H), 3.77 (s, 3H).13C NMR (CDCl3): 168.7, 159.7 (d), 152.9 (d), 133.3, 129.8, 129.2, 127.9, 104.3, 75.6, 53.0.
  • 22
  • [ 79-10-7 ]
  • [ 430-99-9 ]
  • [ 159331-07-4 ]
  • [ 33420-54-1 ]
YieldReaction ConditionsOperation in experiment
With fluorine; sodium fluoride; at -78℃;Inert atmosphere; Example 2: Synthesis of 2,3-difluoropropionic acid (G) [0041] To a solution of acrylic acid in 2H,3H-decafluoropentane was added sodium fluoride as scavenger for HF. The suspension was cooled to -78C under vigorous stirring. Fluorine was introduced to the mixture under the same conditions as example 1. After the reaction, the mixture was filtered and analyzed by GC/MS.
  • 23
  • [ 430-99-9 ]
  • [ 1430422-35-7 ]
  • [ 1430422-36-8 ]
YieldReaction ConditionsOperation in experiment
77% With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; triethylamine; In ethyl acetate; for 60h;Inert atmosphere; To a suspension of 6-bromo-2,2-dimethyl-1-vinyl-2,3-dihydro-1H-inden-1-amine (1.12 g, 4.21 mmol) and 2-fluoropropenoic acid (0.568 g, 6.31 mmol) in dry EtOAc (20 mL)were added 1-propanephosphonic acid cyclic anhydride (T3P) (3.76 mL, 6.31 mmol) and triethylamine (1.47 mL, 10.52 mmol) under nitrogen. After 1.5 h, more 2-fluoropropenoic acid (0.189 g, 2.10 mmol) and 1-propanephosphonic acid cyclic anhydride (T3P) (1.25 mL, 2.10 mmol) was added and stirring continued. After a total of 2.5 days, water was added and the phases were separated. The aq layer was extracted twice with EtOAc and the combined organics were dried over MgSO4, filtered and concentrated. Purification by column chromatography using a gradient of 0-10percent EtOAc in heptane as eluent afforded 1.097 g(77percent) of the title compound. 1H NMR (500 MHz, CHLOROFORM-d) delta 1.10 (s, 3 H), 1.22 (s,3 H), 2.67 -2.77 (m, 2 H), 4.71 (d, 1 H), 5.13 (dd, 1 H), 5.23 (d, 1 H), 5.62-5.75 (m, 1 H), 6.36 (dd, 1 H), 6.62 (br. s., 1 H), 7.08 (d, 1 H), 7.38 (dd, 1 H), 7.53 (d, 1 H). MS (ES-) m/z336,338 [M-H]-
  • 24
  • [ 430-99-9 ]
  • [ 1430422-41-5 ]
  • [ 1430422-42-6 ]
YieldReaction ConditionsOperation in experiment
27% With 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphinane-2,4,6-trioxide; triethylamine; In ethyl acetate; at 0 - 20℃; for 75h;Inert atmosphere; To a suspension of 1?-ethenyl-6?-(3 -fluoropropoxy)-4-[(2H3)methyloxy]-1?,3dihydrospiro[cyclohexane-1,2?-inden]-1?-amine (1.376 g, 4.09 mmol) and in dry ethyl acetate (30 mL) were 1-propanephosphonic acid cyclic anhydride (3.67 mL, 6.14 mmol) and triethylamine (0.570 ml, 4.09 mmol) added at 0 °C under an nitrogen atmosphere. The reaction mixture was then allowed to reach r.t. The mixture was stirred 3 days, then more 1-propanephosphonic acid cyclic anhydride (1.223 mL, 2.05 mmol) and triethylamine (0.285 mL, 2.05 mmol) was added, stirred for another 3h. Water was then added and the phases were separated. The aqueous phase was extracted with EtOAc and the combined organics were dried over Na2SO4 and evaporated. Purification of the residue by silica gel chromatographyusing heptane/ethylacetate 5:1-4:1-3:1 as eluant gave the title compound (0.45 g, 27 percent yield).The product was used as such in the next step.
  • 25
  • [ 430-99-9 ]
  • [ 1430422-08-4 ]
  • [ 1430422-09-5 ]
YieldReaction ConditionsOperation in experiment
43% 2-Fluoroacrylic acid (1.45 g, 16.06 mmol) and HBTU (7.31 g, 19.27 mmol) were dissolved in dichloromethane (30 mL). Triethylamine (3.36 mL, 24.09 mmol) was added and the reaction was stuffed for 6 min. 6?-Bromo-1?-ethenyl-4-methoxy-1?,3?-dihydrospiro[cyclohexane-1,2?-inden]-1?-amine (mixture of isomers) (2.7 g, 8.03 mmol) was added as a solution in dichloromethane (20 mL). The reaction was stuffed for 16 h. The reaction mixture was poured in water. The phases were separated and the aqueous phase extracted with dichloromethane. The combined organic phases were dried over MgSO4, filtered and the solvent evaporated. Column chromatography (silica gel) usingdichloromethane yielded 1.4 g (43 percent) of the title compound. MS (ES-) mlz 406, 408 [M-H]-.
  • 26
  • [ 430-99-9 ]
  • [ 1430422-17-5 ]
  • [ 1430422-18-6 ]
YieldReaction ConditionsOperation in experiment
14.46% 2-Fluoroacrylic acid (3.04 g, 33.70 mmol) and 0-(lH-Benzotriazol-l-yl)-N,N,N',N'- tetramethyluronium hexafluorophosphate (25.6 g, 67.41 mmol) were dissolved in DCM (60 mL). Triethylamine (11.74 mL, 84.26 mmol) was added and the reaction was stirred for 6 min. ( s,4's)-5-Bromo-4'-methoxy-3-vinyl-3H-spiro[benzofuran-2,r-cyclohexan]-3-amine (5.7 g, 16.85 mmol) was added as a solution in DCM (40 mL). The reaction was stirred for 16 h. The reaction mixture was poured in water. The phases were separated and the aqueous phase extracted with DCM. The combined organic phases were dried over MgSO4., filtered and the solvent evaporated. The product was purified by column chromatography using MeOH 0percent to 10percent in DCM to yield 1 g (14.46 percent). 1H NMR (500 MHz, CDC13) delta ppm 1.53 - 1.60 (m, 1 H) 1.60 - 1.72 (m, 2 H) 1.89 - 2.10 (m, 5 H) 3.23 (tt, 3.98 Hz, 1 H) 3.37 (s, 3 H) 4.81 (d, 1 H) 5.18 (dd, 1 H) 5.29 (d, 1 H) 5.64 - 5.77 (m, 1 H) 6.49 - 6.59 (m, 2 H) 6.74 (d, 1 H) 7.32 (d, 1 H) 7.37 (dd, 1 H). MS (ES-) m/z 408, 410 [M-H]~
  • 27
  • [ 430-99-9 ]
  • [ 1430422-25-5 ]
  • [ 1430422-26-6 ]
YieldReaction ConditionsOperation in experiment
37% 2-Fluoroacrylic acid (2.042 g, 22.68 mmol) and O-( 1 H-benzotriazol- 1 -yl)-N,N,N?,N?15 tetramethyluronium hexafluorophosphate (10.32 g, 27.22 mmol) were taken up in DCM (30mL) and TEA (4.74 mL, 34.02 mmol) was added. The reaction was stirred for 6 min 6-bromo-3,3-dimethyl-4-vinylchroman-4-amine (3.2 g, 11.34 mmol) was added as a solution in DCM (20 mL) and the reaction was stirred for 16 h. The reaction mixture was poured into brine and the phases were separated. The aqueous phase was extracted with DCM. The combined organic phases were dried over MgSO4, filtered and the solvent evaporated. Theproduct was purified by column chromatography using EtOAc 0percent to 100percent in heptane to yield1.5 g (37 percent) of the title compound. 1H NMR (500 MHz, DMSO-d6) delta ppm 0.92 (s, 3 H) 0.99(s, 3 H) 3.80 - 3.99 (m, 2 H) 4.72 (d, 1 H) 5.28 (dd, 1 H) 5.36 (d, 1 H) 5.43 - 5.59 (m, 1 H)6.45 (dd, 1 H) 6.77 (d, 1 H) 7.27 (s, 1 H) 7.31 (d, 1 H) 7.55 (br. s., 1 H). MS (ES+) m/z 354,356 [M+H]+
  • 28
  • [ 430-99-9 ]
  • [ 1443234-84-1 ]
  • [ 1443236-32-5 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; 3-[(diethoxyphosphinyl)oxy]-1,2,3-benzotriazin-4(3H)-one; In N,N-dimethyl acetamide; at 50℃; for 12h;Inert atmosphere; Sealed tube; Ethyl 4-(3-aminophenyl)-7H-pyrrolo[2,3- 0.10 mmol), <strong>[430-99-9]2-fluoroacrylic acid</strong> (0.013 g, 0.15 mmol), 3-[(diethoxyphosphoryl)oxy]- l,2,3-benzotriazin-4(3H)-one (0.060 g, 0.20 mmol), and DIPEA (0.070 mL, 0.40 mmol) were suspended in DMA (1.0 mL) in a sealed tube. The reaction mixture was purged with argon and the reaction flask was capped and heated to 50 °C for 12 hours. The completed reaction was passed through a syringe filter, and was directly purified by reverse phase HPLC using an acetonitrile gradient in water with 0.1percent NH4OH modifier to afford ethyl 4-{3-[(2-fluoroacryloyl)amino]phenyl}-7H-pyrrolo[2,3-<i]pyrimidine-5- carboxylate. LRMS (ESI) calc'd for C18H] 6FN403 [M+H]+: 355, found 355. 1H NMR (600 MHz, DMSO-D6) delta 12.99 (s, 1H), 10.44 (s, 1H), 8.91 (s, 1H), 8.32 (s, 1H), 8.09 (t, J= 1.8 Hz, 1H), 7.87 (ddd, J= 1.1, 2.1, 8.0 Hz, 1H), 7.45 (t, J= 7.8 Hz, 1H), 7.40 (dt, J = 1.3, 7.7 Hz, 1H), 5.72 (dd, J = 3.6, 47.6 Hz, 1H), 5.44 (dd, J = 3.7, 15.6 Hz, 1H), 3.85 (q, J = 7.1 Hz, 2H), 0.84 (t, J = 7.1 Hz, 3H).
  • 29
  • [ 430-99-9 ]
  • (S)-3-((3,5-dimethoxyphenyl)ethynyl)-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine [ No CAS ]
  • (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)-2-fluoroprop-2-en-1-one [ No CAS ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; The crude product (5.6 mg) of (S)-3-((3,5-dimethoxyphenyl)ethynyl)-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine obtained in Example 2 as an intermediate, 4-(dimethylamino)but-2-enoic acid hydrochloride (6.3 mg), and HATU (15 mg) were dissolved in DMF (1.0 ml). DIPEA (50 mul) was added thereto, followed by stirring overnight. Chloroform and water were added to the reaction mixture to separate the organic layer. After being washed with a saturated sodium chloride solution, the organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off under reduced pressure. The resulting residue was purified by preparative reversed-phase HPLC purification (water/acetonitrile (0.1percent formic acid)) to obtain the title compound as a colorless, amorphous substance (2.3 mg)
With N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In N,N-dimethyl-formamide; [0293]The crude product (5.6 mg) of (S)-3-((3,5-dimethoxyphenyl)ethynyl)-1-(pyrrolidin-3-yl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine obtained in Example 2 as an intermediate, 4-(dimethylamino)but-2-enoic acid hydrochloride (6.3 mg), and HATU (15 mg) were dissolved in DMF (1.0 ml). DIPEA (50 mul) was added thereto, followed by stirring overnight. Chloroform and water were added to the reaction mixture to separate the organic layer. After being washed with a saturated sodium chloride solution, the organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off under reduced pressure. The resulting residue was purified by preparative reversed-phase HPLC purification (water/acetonitrile (0.1percent formic acid)) to obtain the title compound as a colorless, amorphous substance (2.3 mg). Table 1 shows the physical properties thereof. [0295] In accordance with Example 4, except that <strong>[430-99-9]2-fluoro-acrylic acid</strong> was used in place of 4-(dimethylamino)but-2-enoic acid hydrochloride, the title compound was obtained as a colorless, amorphous substance. Table 2 shows the physical properties thereof.
  • 30
  • [ 430-99-9 ]
  • [ 1609468-24-7 ]
  • [ 1609467-09-5 ]
YieldReaction ConditionsOperation in experiment
With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 0℃; for 0.25h; Example 1345-amino-3-[4-(4-chlorophenoxy)phenyl]-1 -[(3R)-1 -(2-fluoroacryloyl)piperidin-3-yl]-I H-pyrazole-4-carboxamide To a solution of (R)-5-amino-3-(4-(4-chlorophenoxy)phenyl)-1 -(piperidin-3-yl)-1 Hpyrazole-4-carboxamide (prepared as described in Example 13, step 7) (79.1 mg, 0.192 mmol) in N,N-dimethylformamide (2.00 mL)was cooled to 0°C. 2-(1H- Benzotriazol-1-yl)tris(dimethylamino)phosphonium hexafluorophosphate (106 mg, 0.24 mmol), N,N-diisopropylethylamine (65.3 mg, 0.48 mmol) and <strong>[430-99-9]2-fluoroacrylic acid</strong> (21.69mg, 0.24 mmol) were added at 0°C. The reaction mixture was stirred for 15 mm at 0°C and then quenched by pouring over ice water. The solid was filtered and purified by reverse phase HPLC to afford the title compound. MS (M+H) m/z 484.1.
  • 31
  • [ 430-99-9 ]
  • [ 1609468-26-9 ]
  • [ 1609467-25-5 ]
YieldReaction ConditionsOperation in experiment
With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 0℃; for 0.5h; Example 1505-amino-3-[4-(2,4-difluorophenoxy)phenyl]-1 -[(3R)-1 -(2-fluoroacryloyl)piperidin-3- yl]-l H-pyrazole-4-carboxamide To a solution of (R)-5-amino-3-(4-(2,4-difluorophenoxy)phenyl)-1 -(piperidin-3-yl)-H-pyrazole-4-carboxamide (prepared as described in Example 26, step 1) (200 mg,0.48 mmol) in N,N-dimethylformanide (3 mL) at 0 °C was added (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (235 mg, 0.53 mmol), N, N-diisopropylethylamine (0.22 mL, 1.21 mmol) and <strong>[430-99-9]2-fluoroacrylic acid</strong> (43.6 mg, 0.48 mmol). After 30 mm, the mixture was poured into water/ethyl acetate and the layers seperated. The organic layer was dried (Na2SO4) and concentrated. The crude product was purified by reverse-phase HPLC to afford the title compound. 1H NMR (600 MHz,DMSO-d6) 6 ppm 1.57 (m, 1 H), 1.89 - 2.09 (m, 3 H), 2.97 (m, 0.5 H), 3.22 (m, 1 H),3.61 (m, 0.5 H), 3.97 (m, 1 H), 4.13 - 4.42 (m, 2 H), 5.11 - 5.38 (m, 2 H), 6.45 (br. s., 2H), 7.00 - 7.09 (m, 2 H), 7.15 - 7.24 (m, 1 H), 7.42-7.38 (m, 1 H), 7.51 - 7.59 (m, 3 H).MS (M+H) m/z486.1.
  • 32
  • [ 430-99-9 ]
  • [ 1609468-35-0 ]
  • [ 1609467-40-4 ]
YieldReaction ConditionsOperation in experiment
With benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 0℃; for 0.5h; Example 1655-amino-I -[(3R)-I -(2-fluoroacryloyl)piperidin-3-yl]-3-(4-[6-(trifluoromethyl)pyridin-2-yl]oxy}phenyl)-I H-pyrazole-4-carboxamide (Benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (218 mg, 0.49 mmol), diisopropylamine (0.2 mL, 1.12 mmol) and <strong>[430-99-9]2-fluoroacrylic acid</strong>(40.3 mg, 0.45 mmol) were added to a solution of (R)-5-amino-1-(piperidin-3-yl)-3-(4- ((6-(trifluoromethyl)pyridin-2-yl)oxy)phenyl)- 1 H-pyrazole-4-carboxam ide (prepared as described in Example, step 2) (200 mg, 0.45 mmol) in N,N-dimethylformamide (3 mL) at 0 °C. After 30 mm, the mixture was poured into water/ethyl acetate and the layers separated. The organic layer was dried (Na2504) and concentrated. The crude productwas purified by reverse phase HPLC to afford the title compound. 1H NMR (600 MHz,DMSO-d6) 6 ppm 8.18 (t, J=7.69 Hz, 1 H), 7.70 (d, J=7.47 Hz, 1 H), 7.62 (d, J=8.35 Hz,2 H), 7.41 (d, J=8.35 Hz, 1 H), 7.27 - 7.34 (m, 2 H), 6.45 (s, 2 H), 5.31 (br. s., 1 H), 5.11-5.26 (m, 2 H), 4.10-4.44 (m, 3 H), 3.79-4.06 (m, 1 H), 3.66 (m, 1 H), 3.26 (m, 1 H),2.96 (m., 1 H), 2.07 (m, 1 H), 1.95 (d, J=12.30 Hz, 1 H), 1.58 (m, 1 H). MS (M+H) m/z519.1.
  • 33
  • [ 430-99-9 ]
  • [ 132959-53-6 ]
  • (S)-1-(2-allylpyrrolidin-1-yl)-2-fluoroprop-2-en-1-one [ No CAS ]
  • 34
  • [ 430-99-9 ]
  • [ 1208242-58-3 ]
  • N-allyl-N-(2,4-dimethoxybenzyl)-α-fluoroacrylamide [ No CAS ]
  • 35
  • [ 798542-73-1 ]
  • [ 430-99-9 ]
  • N-allyl-N-(2,4-dimethoxybenzyl)-α-fluoroacrylamide [ No CAS ]
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 430-99-9 ]

Fluorinated Building Blocks

Chemical Structure| 2343-89-7

A272348 [2343-89-7]

Methyl 2-fluoroacrylate

Similarity: 0.80

Alkenyls

Chemical Structure| 2343-89-7

A272348 [2343-89-7]

Methyl 2-fluoroacrylate

Similarity: 0.80

Chemical Structure| 7704-72-5

A209158 [7704-72-5]

Fumaric acid xpotassium salt

Similarity: 0.50

Aliphatic Chain Hydrocarbons

Chemical Structure| 2343-89-7

A272348 [2343-89-7]

Methyl 2-fluoroacrylate

Similarity: 0.80

Chemical Structure| 7704-72-5

A209158 [7704-72-5]

Fumaric acid xpotassium salt

Similarity: 0.50